Showing results (11-20 of 453) with videos related to
Sort By:
Pageof 46
Expert Opinion on Investigational Drugs|December 5, 2008
Development of PARP inhibitors in oncologyJordi Rodon, Maria D Iniesta, Kyriakos PapadopoulosRecent Patents on Anti-Cancer Drug Discovery|February 8, 2011
Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2Rodrigo Dienstmann, Jordi Rodon, Ben Markman, et al.Nature Reviews. Clinical Oncology|February 13, 2013
Development of PI3K inhibitors: lessons learned from early clinical trialsJordi Rodon, Rodrigo Dienstmann, Violeta Serra, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2013
Genomic medicine frontier in human solid tumors: prospects and challengesRodrigo Dienstmann, Jordi Rodon, Jordi Barretina, et al.Journal of Immunotherapy and Precision Oncology|September 2, 2024
Decentralized Clinical Trials in Early Drug Development-A Framework ProposalDiogo J Silva, Blessie Elizabeth Nelson, Jordi RodonThe Oncologist|December 3, 2011
Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugsRodrigo Dienstmann, Irene Braña, Jordi Rodon, et al.Molecular Cancer Therapeutics|April 22, 2014
Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitorsRodrigo Dienstmann, Jordi Rodon, Violeta Serra, et al.Journal for Immunotherapy of Cancer|March 25, 2022
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancerTimothy A Yap, Alberto Bessudo, Erika Hamilton, et al.Journal of Gastrointestinal Cancer|April 29, 2023
Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical TrialsRishi Surana, Graciela Nogueras Gonzalez, Jane Rogers, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
What It Takes to Improve a First-Generation Inhibitor to a Second- or Third-Generation Small MoleculeJordi Rodon Ahnert, Nathanael Gray, Tony Mok, et al.Pageof 46